EZH2 and head and neck squamous cell carcinoma: Additional investigations have also exhibited that in HNSCC, EZH2 can obstruct EMT processes both in vitro and in vivo by controlling downstream signaling pathways, including the STAT3/vascular endothelial growth factor receptor 2 (VEGFR2) axis.